Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 39 - Medicinal preparations containing antigens or antibodies
Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248)
11/2003
11/13/2003WO2002074903A3 Comparative mycobacterial geneomics as a tool for identifying targets for the diagnosis, prophylaxis or treatment of mycobacterioses
11/13/2003WO2002069198A3 Hla ligand database utilizing predictive algorithms and methods of making and using same
11/13/2003WO2002057302A8 A virus causing respiratory tract illness in susceptible mammals
11/13/2003WO2002056893A8 Novel receptors for $i(helicobacter pylori) and use thereof
11/13/2003WO2002048715A3 Inflammatory markers for detection and prevention of diabetes mellitus
11/13/2003WO2002014362A3 A hepatitis c virus non-structural ns3/4a fusion gene
11/13/2003WO2002014348B1 Glycoproteins and methods of use thereof
11/13/2003US20030213004 Composition comprising ribozyme/monoclonal antibody fusion protein for treating cell proliferative disorders; anticarcinogenic/antiproliferative agents
11/13/2003US20030213003 Preparing and recoverng genetically engineered fusion protein for treating diabetes
11/13/2003US20030212044 Treatment of HIV
11/13/2003US20030212029 Polymerase chain reactions; immunology moderators
11/13/2003US20030212027 Vaccine formulations and methods for immunizing an individual against shed antigen specific B cells
11/13/2003US20030212026 Induce immunology response
11/13/2003US20030212008 Farnesyl protein transferase inhibitor combinations with further anti-cancer agents
11/13/2003US20030211997 Mimetic peptides for an epitope of apolipoprotein B-100, concatemers of the peptides, and modified peptides, and compositions comprising the same
11/13/2003US20030211996 Virus like particles
11/13/2003US20030211971 Compositions and methods for prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases with compositions comprising unfractionated cellular proteins
11/13/2003US20030211964 Method of inhibiting pathogenicity of infectious agents
11/13/2003US20030211613 Methods of altering calcium transport
11/13/2003US20030211597 Genetically engineered hepatitis C viral (HVC) particle for use in prevention, diagnosis and prognostication of viral infections; immunoassays; genetic vaccines diagnosis
11/13/2003US20030211592 Methods of terminal sterilization of biological products
11/13/2003US20030211576 Comprises nucleotide sequences coding membrane protein for use in treatment of tumors and cell proliferative diseases; antiinflammatory agents
11/13/2003US20030211541 Using immunological means to identify growth differentiation factor-14 (GDF-14) for treating cell proliferative and immunological disorders; gene expression inhibition; antiproliferative agents
11/13/2003US20030211521 Breast cancer antigen
11/13/2003US20030211520 Comprises urogenital system specific protein for diagnosing and treating tumors; antiproliferative agents; genetic vaccine
11/13/2003US20030211515 Comprises nucleotide sequences coding matrix protein for diagnosing and treating cancer
11/13/2003US20030211485 Novel proteins and nucleic acids encoding same
11/13/2003US20030211467 Using monoclonal antibody for diagnosis, prevention and treatment of viral infections; immunotherapy; genetic vaccine
11/13/2003US20030211463 Monoclonal antibody for diagnosis, prevention and treatment of viral infections; immunotherapy
11/13/2003US20030211165 Anticancer agents; mixture of hydrophilic, crosslinked polymer and drugs
11/13/2003US20030211158 Microgel particles for the delivery of bioactive materials
11/13/2003US20030211143 Emulsion and micellar formulations for the delivery of biologically active substances to cells
11/13/2003US20030211122 Mucosal microparticle conjugate vaccine
11/13/2003US20030211120 Hepatitis vaccines containing 3-O-deacylated monophoshoryl lipid A
11/13/2003US20030211118 Immunizing compositions and methods of use
11/13/2003US20030211117 Synthetic antigen for the detection of aids-related disease
11/13/2003US20030211116 Polypeptide; anticancer agents; cytotoxic lymphocyte response
11/13/2003US20030211115 Adjuvant compositions for mucosal and injection delivered vaccines
11/13/2003US20030211114 Vaccine for Pseudomonas aeruginosa
11/13/2003US20030211113 Administering immunosuppressant
11/13/2003US20030211112 EGFR ligands and methods of use
11/13/2003US20030211106 Binding tumor necrosis factor to antibody
11/13/2003US20030211104 Methods of using cytokine antagonists to treat HIV infection and AIDS
11/13/2003US20030211103 Use of primate IFN-gamma binding molecules
11/13/2003US20030211102 Immunogens for treatment of neoplastic and infectious disease
11/13/2003US20030211100 Gene therapy; nucleic acid coding immunoglobulins; anticancer agents
11/13/2003US20030211098 Pretreatment of animal with antibodies to sensitize animal; controlling dosage
11/13/2003US20030211096 Detection of genes which amplification genome cells; anticancer, antitumor agent
11/13/2003US20030211095 Peptide for regulation of urokinase plasminogen activator and method of optimizing therapeutic efficacy
11/13/2003US20030211092 Genetic engineering; gene expression; culture product
11/13/2003US20030211090 Isolation culture product; cell differentiation
11/13/2003US20030211089 Transgenic algae for delivering antigens to an animal
11/13/2003US20030211047 High speed absorption; mixture of aqueous polar solvent, propellant, active material and flavor
11/13/2003US20030211039 Method of diagnosing, monitoring, staging, imaging and treating colon cancer
11/13/2003US20030211038 Calibration sensitive toxicity to radioimmunotherapy; administering radioactive antibodies; measurement bone marrow
11/13/2003CA2485216A1 Therapeutic use of pacap, maxadilan, pacap receptor agonist and/or adcyap1r1 in the treatment of cns disorders
11/13/2003CA2485098A1 Use of heat shock proteins to enhance efficacy of antibody therapeutics
11/13/2003CA2484965A1 Encapsulated cells to elicit immune response
11/13/2003CA2484420A1 Antibodies specific for human cd22 and their therapeutic and diagnostic uses
11/13/2003CA2484185A1 Site specific listeria integration vectors and methods for using the same
11/13/2003CA2484182A1 Novel antibody binding tcr and tirc7 and its use in therapy and diagnosis
11/13/2003CA2484155A1 Antagonists of factor viii interaction with low-density lipoprotein receptor-related protein
11/13/2003CA2483912A1 Alcam and alcam modulators
11/13/2003CA2483909A1 Novel tissue factor targeted thrombomodulin fusion proteins as anticoagulants
11/13/2003CA2483653A1 Dengue tetravalent vaccine containing a common 30 nucleotide deletion in the 3'-utr of dengue types 1,2,3, and 4, or antigenic chimeric dengue viruses 1,2,3, and 4
11/13/2003CA2483552A1 Calicheamicin derivative-carrier conjugates
11/13/2003CA2483050A1 Optimization of transgene expression in mammalian cells
11/13/2003CA2482967A1 Binary or polynary targeting and uses thereof
11/13/2003CA2482411A1 Antibody fragments specific for human carncinoembryonic antigen (cea)
11/13/2003CA2480777A1 Methods of using cytokine antagonists to treat hiv infection and aids
11/13/2003CA2480008A1 Use of il-13 receptor subunit alpha 2 as an anti-cancer vaccine
11/13/2003CA2462879A1 Immunoconjugates for the treatment of tumours
11/12/2003EP1361286A1 Method for detection of cancer
11/12/2003EP1361277A1 Optimization of transgene expression in mammalian cells
11/12/2003EP1361271A2 Isolated nonapeptide derived from MAGE-3 gene and presented by HLA-A1, and uses thereof
11/12/2003EP1361269A1 Delivery of gene products via mesangial cells expressing an exogenous gene
11/12/2003EP1361267A2 Mesenchymal stem cells and their use
11/12/2003EP1360963A2 Ganglioside-KLH conjugate vaccines with QS-21
11/12/2003EP1360498A2 Latent human tuberculosis model, diagnostic antigens, and methods of use
11/12/2003EP1360496A1 Methods and reagents for the rapid and efficient isolation of circulating cancer cells
11/12/2003EP1360299A2 The genome of a bifidobacterium
11/12/2003EP1360297A2 Ragweed allergens
11/12/2003EP1360293A2 Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or virus resistance and their use as medicines
11/12/2003EP1360291A2 Human polynucleotides and polypeptides encoded thereby
11/12/2003EP1360276A2 In vitro system for replication of rna-dependent rna polymerase (rdrp) viruses
11/12/2003EP1360208A1 Induvidualized anti-cancer antibodies
11/12/2003EP1360203A1 Antibodies to non-functional p 2 x 7 receptor diagnosis and treatment of cancers and other conditions
11/12/2003EP1360199A2 Treatment involving dkk-1 or antagonists thereof
11/12/2003EP1360198A2 Novel polypeptides and nucleic acids encoded thereby
11/12/2003EP1360195A2 H. influenzae antigen basb213
11/12/2003EP1360194A2 Systems for expression of heterologous proteins in m. capsulatus
11/12/2003EP1360193A1 Method for purifying the helicobacter adhesin-like protein a (alpa)
11/12/2003EP1359942A1 Targetted anti-tumor drug delivery systems
11/12/2003EP1359938A2 Method for treating psoriasis by using an il-17d antagonist
11/12/2003EP1359937A1 Altered peptide ligands
11/12/2003EP1359922A1 Novel receptors for $i(helicobacter pylori) and use thereof
11/12/2003EP1359899A1 Composition and method for controlled release injections
11/12/2003EP1359799A2 Methods and compositions for the control of coccidiosis
11/12/2003EP1117677B1 Ligand presenting assembly (lpa), method of preparation and uses thereof
11/12/2003EP1112083B1 Use of an angiogenic factor for the treatment of microvascular angiopathies
1 ... 1197 1198 1199 1200 1201 1202 1203 1204 1205 1206 1207 1208 1209 1210 1211 1212 1213 1214 1215 1216 1217 ... 1823